Followers | 9 |
Posts | 750 |
Boards Moderated | 0 |
Alias Born | 10/19/2008 |
Saturday, March 01, 2014 5:00:00 PM
Ask them. Give them a call to find out. You might just find is has something to do with the facts. Facts like:
NNVC therapeutic efficacy testing show remarkable results. Standardized test protocols with mice specially developed by those in the medical research community to have human susceptibility traits injected with 1000x viral loads required to ensure death. Standard industry protocols that measure efficacy by the time it takes to die for a treated mouse versus the control mice. Unprecedentedly, large percentages actually survive! Almost unheard of efficacy!
NNVC therapeutics shown to have similar efficacy in both injectable and oral forms.
NNVC therapeutics used in both forms show no apparent toxicity issues to date. Specific testing being currently planned and prepared for to verify.
From a comparative and historical perspective, stock dilution has been minimal demonstrating good stewardship and results per unit dollar achievement.
NNVC’s work good enough that is was awarded an orphan drug development designation in both the United States and Europe.
NNVC work good enough to now be an official candidate for a FDA Priority Review Voucher.
NNVC science independently confirmed by independent researchers in the area of pathogenesis and epidemiology of infectious diseases.
NNVC currently has sufficient funds to support 2 years of operations and into first human trials.
NNVC major insider purchases more shares from the open market in recent weeks.
NNVC therapeutics appear to be of a programmable design that can target nearly any type of virus in a matter of weeks!
Oh, and that is just to name a few possible reasons.
In the not too distant future, it just might be an NNVC nanoviricide that saves your life, or the life of a loved one. Do your own DD. Beware of misinformation. Read, study, think; a process that behooves us all.
Wishing all the best of good buys!
HS
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM